This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.
Gruber FXE, Lamaek T, Anonli A, Sovershaev MA, Olsen M, Gedde-Dahl T et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005; 19: 2159–2165.
Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110: 727–734.
Willis SG, Lange T, Demehri S, Otto S, Crossmann L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137.
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G . Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: 1–13.
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.
Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 2004; 50: 1205–1213.
ÓHare C, Eide CA, Deininger MWN . BCR-ABL kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 2007; 110: 2242–2249.
Acknowledgements
We thank Dr K Krohn (Core unit ‘DNA Technologies’, IZKF Leipzig, Germany) for the sequence analysis. This work was supported by Novartis Pharma GmbH (Nürnberg, Germany).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pelz-Ackermann, O., Cross, M., Pfeifer, H. et al. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia 22, 2288–2291 (2008). https://doi.org/10.1038/leu.2008.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.180
This article is cited by
-
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
Leukemia (2012)
-
Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing
Molecular Diagnosis & Therapy (2012)